Replimune Group's stock surged following Citigroup's upgrade to Overweight and a favorable FDA advisory panel vote supporting its advanced melanoma drug, RP1. The FDA panel voted 10-3 in favor of the drug's effectiveness in combination with nivolumab, despite some concerns about trial data. This positive regulatory step boosts investor confidence and could accelerate the drug's path to market for patients with advanced melanoma who have limited treatment options.
Novo Nordisk announced that its ZEUS phase 3 trial testing ziltivekimab, an IL-6 pathway inhibitor, in over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammation did not reduce major adverse cardiovascul...
Perella Weinberg Partners reported Q2 2026 revenues of $157 million, a 1% increase from last year, with adjusted pre-tax income of $27 million and adjusted EPS of $0.20. Despite a 17% revenue decline in the first half of 2026, the firm is investing i...
Perella Weinberg Partners announced the promotion of eight managing directors to partners, recognizing their achievements and leadership in sectors like financial services, healthcare, and capital solutions. This move highlights the firm's confidence...
Artem Voinov, Chief Business Development Officer at ICODA, will attend Blockchain Rio 2026, Latin America's largest blockchain conference, held August 12–13 in Rio de Janeiro. The event gathers regulators, financial institutions, and Web3 leaders, em...
Weekly trading volume for real-world asset (RWA) perpetual futures reached $61.7 billion, nearly matching Bitcoin perpetual futures at 99.2% across platforms like Hyperliquid and Binance. Tokenized equities and commodities are the main drivers, with ...
